Clinical trials: Allogenic Disease
Polymyositis, Dermatomyositis
Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis
To determine the maximum tolerated dose (MTD) based on the safety and tolerability after single-dose administration of PN-101 in patients with refractory polymyositis or dermatomyositis.
- Trial name
- NCT04976140
- Testing
- PN-101
- Where
- 3 sites in South Korea
- Volunteers
- 9 people
- Sponsor
- Paean Biotechnology Inc.
Acute Myeloid Leukemia
Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.
The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.
- Trial name
- AML_MenALLO (NCT07627568)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Freiburg
Acute Myeloid Leukemia
RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT
To evaluate the safety and tolerability of RC1012 injection infusion in AML Patients after Allo-HSCT
- Trial name
- NCT05858814
- Testing
- RC1012 injection (allo-DNT cells)
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Guangdong Ruishun Biotech Co., Ltd
Systemic Sclerosis
RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis
This is a Phase I, single arm, open label, single center pilot study to assess a reduced-intensity conditioning regimen, bone marrow transplantation with high dose cyclophosphamide (PTCy) in recipients with refractory systemic…
- Trial name
- NCT05298358
- Testing
- RIC alloBMT w PTCy in refractory SSc
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non Hodgkin's Lymphoma, Hodgkin Disease
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
The proposed study is based on our observation of paradoxical tumor regression after rejection of the donor graft in conjunction with the results of our murine experiments.
- Conditions
- Non Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma
- Trial name
- RLI (NCT00909948)
- Testing
- Fludarabine and total body irradiation, Total body irradiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Leukemia, Nonlymphoblastic, Acute
AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients
The AML96 study examines the feasibility of a risk-adapted postremission treatment strategy including related and unrelated allogeneic stem cell transplantation for high risk AML patients and related allogeneic and autologous…
- Trial name
- NCT00180115
- Testing
- Cytarabine Dosage
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Technische Universität Dresden
Haematological Malignancies, Allogeneic Stem Cell Transplant
CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation
The investigators propose a nonrandomized, Phase I study to assess the safety of infusion of NK cells that will be selected from sibling donors and infused to patients with hematological malignancies early following allogeneic…
- Conditions
- Haematological Malignancies, Allogeneic Stem Cell Transplant, CD56+CD3- NK Cells
- Trial name
- NCT01336478
- Testing
- Infusion of donor derived ex-vivo selected NK cells to patients after transplant, Haematology / Blood chemistry sampling
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Imperial College London
Acute Transplant Rejection in Patients Receiving Allogeneic Renal Transplant
Generic Mycophenolate Mofetil Safety Study for Prophylaxis in de Novo Renal Transplant Patients in Jordan
The purpose of this observational study was to assess the safety and efficacy of generic mycophenolate mofetil in de novo renal transplant patients in Jordan where no visits or intervention(s) additional to the daily practice…
- Trial name
- MyOra-PASS (NCT03517982)
- Testing
- Mycophenolate Mofetil
- Where
- Jordan
- Volunteers
- 12 people
- Sponsor
- Hikma Pharmaceuticals LLC
Relapsed / Refractory Autoimmune Hemolytic Anemia
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Autoimmune Hemolytic Anemia
This is an open label, single-site, dose-escalation study in up to 18 participants with relapsed or refractory Autoimmune hemolytic anemia.
- Trial name
- NCT06920446
- Testing
- UCAR T-cell group
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Mesenchymal Stromal Cells, Cornea
Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells
This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of locally delivered allogeneic mesenchymal stromal cells (MSC) for promoting corneal…
- Conditions
- Mesenchymal Stromal Cells, Cornea, Safety, Corneal Defect
- Trial name
- NCT04626583
- Testing
- Allogeneic MSC
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Illinois Chicago
Respiratory Distress Syndrome, Adult
Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)
This was a Phase 2a, randomized, double-blind, placebo-controlled, multi-center trial to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in…
- Trial name
- START (NCT02097641)
- Testing
- Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Michael A. Matthay
Multiple Myeloma
Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.
- Trial name
- NCT00116441
- Testing
- Therapeutic Cellular Vaccine, GM-CSF Producing
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Cell Genesys
Graft vs Host Disease, Multiple Myeloma
Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
Both patients and marrow donors are treated on Regimen A; patients then proceed to Regimen B. The following acronyms are used: ABM Allogeneic Bone Marrow BU Busulfan, NSC-750 CF Leucovorin calcium, NSC-3590 CTX Cyclophosphamide…
- Trial name
- NCT00001561
- Testing
- Myeloma Immunoglobulin Idiotype Vaccine-KLH, GM-CSF
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm
Fecal Microbiota Transplantation for Steroid Resistant/Dependent Acute GI GVHD
The purpose of this study is to evaluate the efficacy and safety of fecal microbiome transplantation in patients with steroid resistant/dependent acute gastrointestinal graft-versus-host disease (GVHD).
- Trial name
- FEMITGIGVHD (NCT03812705)
- Testing
- fecal microbiome transplantation
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Acute Myeloid Leukemia
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
This study will examine the safety and anti-leukemic profile of SGN-CD33A (vadastuximab talirine) in patients with relapsed chemo-resistant AML, who are given vadastuximab talirine in sequence with standard treatments before a…
- Trial name
- NCT02614560
- Testing
- Fludarabine, Melphalan, vadastuximab talirine
- Where
- 11 sites in United States
- Volunteers
- 14 people
- Sponsor
- Seagen Inc.
Graft vs Host Disease
Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease
Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa possesses potent anti-inflammatory and immunosuppressive properties.
- Trial name
- NCT02478424
- Testing
- Cannabidiol, cyclosporine, Methotrexate
- Volunteers
- 10 people
- Sponsor
- Rabin Medical Center
Allogeneic Transplantation (Non T-cell Depleted)
Phase I Clinical Trial to Assess Safety of UV Phototherapy for the Prevention of GVHD Post Allogeneic SCT
The primary goal of thos study is to assess safety of Ultraviolet (UV) Phototherapy for the Prevention of Graft versus Host Disease after allogeneic stem cell transplantation (Phase I - Clinical trial).
- Trial name
- NCT00524953
- Testing
- EUMATRON - EN 600 NT
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination
The reconstitution of a functioning immune system after allogeneic stem cell transplantation takes months to years. Particularly memory B-lymphocytes reconstitute poorly with the current conditioning regimes.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Non Hodgkin's Lymphoma
- Trial name
- B-cell therapy (NCT02007811)
- Testing
- allogeneic donor derived B-lymphocytes
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Hematologic Diseases, Stem Cell Transplant Complications
Prospective Survey of CMV, Herpesviruses Infections and Diseases in Allo-HSCT
Prospective observational study of epidemiological surveillance, multicenter, non-profit, spontaneous, Italian with objective to describe the incidence of CMV infections and diseases in adult and pediatric patients undergoing…
- Conditions
- Hematologic Diseases, Stem Cell Transplant Complications, Cytomegalovirus Viremia, Herpesvirus Infection
- Trial name
- CYTOALLOSURVEY (NCT04412811)
- Where
- 50 sites in Italy
- Volunteers
- 1,310 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Acute Respiratory Distress Syndrome, Adult
Treatment of Severe Acute Respiratory Distress Syndrome With Allogeneic Bone Marrow-derived Mesenchymal Stromal Cells
This is a multi-center, open-label, non-randomized controlled trial. Patients with viral-induced acute respiratory distress syndrome (ARDS) on extracorporeal membrane oxygenation (ECMO) will be eligible.
- Trial name
- NCT02215811
- Testing
- Mesenchymal stromal cells
- Where
- 2 sites in Sweden
- Volunteers
- 10 people
- Sponsor
- Karolinska University Hospital